How far have AAV platforms taken us? Lessons from a CDMO on accelerating time-to-clinic

Time to clinic remains a critical success factor for both emerging biotech’s and established pharmaceutical organisations in the cell and gene therapy (CGT) sector. Driven by competitive pressures and milestone-based funding models, alongside a commitment to deliver life-changing treatments to patients in need, the urgency to advance novel therapies into the clinic has never been greater. In response, a range of adeno-associated virus (AAV) platform technologies have emerged, each aiming to streamline development and reduce timelines. This article explores how far platform-based approaches can go in accelerating time to clinic. Drawing on real-world insights from a contract development and manufacturing organisation (CDMO), we examine key process and technology innovations, the pivotal role of analytics in expediting development, and the future evolution of AAV platforms.

Please enter your email to access content Read now